Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Preliminary Safety And Anti-Tumor Activity Of Xmab13676, An Anti-Cd20 X Anti-Cd3 Bispecific Antibody, In Patients With Relapsed/Refractory Non-Hodgkin'S Lymphoma And Chronic Lymphocytic Leukemia

Krish Patel,Jean-Marie Michot,Asher A. Chanan-Khan,Gilles A. Salles,Guillaume Cartron,Frederic Peyrade,Reda Bouabdallah,Erin G. Reid,Sheeba K. Thomas,William G. Wierda,David Liebowitz,John M. Pagel,Vincent Ribrag,M. Wayne Saville,Chelsea M. Johnson,Thomas Ly,Tycel J. Phillips

BLOOD（2019）

Cited 21|Views35
No score
Abstract
Introduction: XmAb13676 is a humanized bispecific antibody that binds both CD20 and CD3 in order to recruit cytotoxic T cells to kill CD20 expressing malignant cells. Interim results of an ongoing first-in-human, dose-escalation study (XmAb13676-01; NCT02924402) in subjects with relapsed/refractory (R/R) non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are reported here.
More
Translated text
Key words
bispecific antibody,chronic lymphocytic leukemia,lymphoma,xmab13676,anti-tumor,non-hodgkin
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined